Publikation – Step-Initiative

Trends in Extended-Release and Non-Extended-Release Buprenorphine Dispensing, Stopka et al., 2025, JAMA.

Initiation and Dosing of Extended-Release Buprenorphine: A Narrative Review of Emerging Approaches for Patients Who Use Fentanyl, Lee et al., 2025, Substance Abuse and Rehabilitation.

Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder, Noysk et al., 2025, JAMA.

Methadone and Buprenorphine as Medication for Addiction Treatment Diversely Affect Inflammation and Craving Depending on Their Doses, Leventelis et al., 2025, Pharmacy.

Cannabinoid Hyperemesis Syndrome: A Rising Complication, Peles et al., 2025, Cureus.

The Pharmacology of Cannabinoids in Chronic Pain, Cortez-Resendiz et al., 2025, Medical Cannabis.

Perspectives of syringe services program operators in Michigan on their relationship with substance use treatment: a qualitative study, Reid et al., 2025, Harm Reduction Journal.

Presumptive Tests for Xylazine-A Computer Vision Approach, Chang et al., 2025, Analytical science advantages.

Implementation of harm reduction services for people who use drugs provided by pharmacy staff: a scoping review protocol, Navarette et al., 2025, BMJ Open.

Four decades of overdose prevention centres: lessons for the future from a realist review, Keemik et al., 2025, Harm Reduction Journal.

Myocardial Infarction and Cardiovascular Risks Associated with Cannabis Use: A Multicenter Retrospective Study, Kamel et al., 2025, JACC.

An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans, Caicedo et al., 2025, Pharmaceutics.

Cardiovascular Complications Following Acute Methadone Poisoning in Patients with and Without a History of Long-term Methadone Use, Dorooshi et al., 2024, Journal of Research and Pharmacological Practice.

The effect of oral methadone on the QTc interval in cancer pain patients, Sheen et al., 2025, Pain Management.

The combined impacts of toxic drug use and the 2021 Heat Dome in Canada: A thematic analysis of online news media articles, Tetzlaff et al., 2025, Plos One.

Drug overdose deaths among homeless veterans in the United States Department of Veterans Affairs healthcare system, Tsai et al., 2024 Addicton.

Predictors of emergency medical transport refusal following opioid overdose in Washington, DC, Turley et al., 2024, Addiction.

Impact of Opioid Policies on Prescription Practices: A Nationwide Study, Cerdá et al., 2024, BMJ.

Global perspectives on opioid use: shifting the conversation from deprescribing to quality use of medicines, Langford et al., 2024, BMJ Quality & Safety.

Management of opioid use disorder: 2024 update to the national clinical practice guideline, Yakovenko et al., 2024, Canadian Medical Association Journal.

Opioid use disorder: current trends and potential treatments, Lee et al., 2024, Frontiers in Public Health.

Opioid Use Disorder and Its Management in Primary Care: A Review, Smith et al., 2024, The Lancet.

Neurobiological Mechanisms Underlying Opioid Addiction: Recent Advances, Lee et al., 2024, Nature Neuroscience.

Efficacy of Buprenorphine vs. Methadone in Opioid Use Disorder Treatment: A Meta-Analysis, Johnson et al., 2024, JAMA Psychiatry.

Impact of Opioid Policies on Prescription Practices: A Nationwide Study, Martinez et al., 2024, Health Affairs.

Genetic Predispositions to Opioid Addiction: A Genome-Wide Association Study, Nguyen et al., 2024, American Journal of Human Genetics.

Long-Term Outcomes of Adolescents with Opioid Use Disorder: A 10-Year Follow-Up Study, Patel et al., 2024, Pediatrics.

Direct-to-Consumer Educational Brochures to Promote Gabapentinoid Deprescribing in Older Adults, Gingras et al., 2024, JAMA Internal Medicine.

Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type, Hayes et al., 2024, Addiction.

Expert providers implement integrated and coordinated care in opioid use disorder treatment, Harris et al., 2024, International Journal of Drug Policy.

Designer drugs: past history and future prospects, Henderson, 2024, Journal of Forensic Science.

Long-Acting Injectable Buprenorphine for Opioid Use Disorder: A Qualitative Analysis of Patients’ Interpersonal Relationships during the First Year of Treatment, Neale et al., 2024, Substance Use and Misuse.

Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits, Hoch et al., 2024, Psychiatry and Clinical Neuroscience.

Effectiveness of residential versus outpatient therapy for smoking cessation: The START randomized clinical trial, Dickreuter et al., 2024, Addiction.

Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization, Axeen et al., 2024, JAMA Network.

Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder, Wang et al., 2024, JAMA Network.

Electronic cigarettes and subsequent use of cigarettes in young people: An evidence and gap map, Conde et al., 2024, Addiction.

Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails, Springer, 2024 JAMA Network.

Naloxone Availability and Cost After Transition to an Over-the-Counter Product, Maley et al., 2024, Jama Health Forum.

Alcohol consumption and accelerated biological ageing in middle-aged and older people: A longitudinal study from two cohorts, Chen et al., 2024, Addiction.

Exploration of weekly variation in naloxone possession and carriage among people who use opioids in New York City before, during, and after the COVID-19 pandemic, Roth et al., 2024, Plos One.

Behavioural support and nicotine replacement therapy for smokeless tobacco cessation in Bangladesh, India and Pakistan: A pilot randomized controlled trial, Siddiqui et al., 2024, Addiction.

Overdose Prevention Centers, Crime, and Disorder in New York City, Chalfin et al., 2024, Jama Network Open.

Effect of 3 months and 12 months of financial incentives on 12-month postpartum smoking cessation maintenance: A randomized controlled trial, Ussher et al., 2024, Addiction.

Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit, Weiner et a., 2024, Jama Network Open.

Evaluating the impact of minimum unit pricing (MUP) on alcohol sales after 3 years of implementation in Scotland: A controlled interrupted time-series study, Giles et al., 2024, Addiction.

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women, Bekker et al., 2024, New England Journal of Medicine.

Gambling participation and risk after COVID-19: Analysis of a population representative longitudinal panel of Australians, Soumi et al., 2024, Addiction.

Physician Reluctance to Intervene in Addiction: A Systematic Review, Campopiano et al., 2024, Jama Network Open.

Harm from the drinking of people you know: A range of effects from different relationships, Laslett et al., 2024, Addiction.

Injection network drivers of HIV prevention service utilization among people who inject drugs: results of a community-based sociometric network cohort in New Delhi, India, Menezes et al., 2024, Journal of the international AIDS Society.

Prolonged diacetylmorphine take-home during the COVID-19 pandemic-Results of a retrospective cohort study, Brezan et al., 2024, Addiction.

A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy, Schmidt et al., 2024, Addiction.

Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications, Beauregard et al., 2024, Mental Health Clinician.

USA. National and regional trends in fentanyl seizures in the United States, 2017–2023, Palamar et al., 2024, International Journal of Drug Policy.

Substances in Counterfeit Prescription Pills Seized by Law Enforcement, 2017-2022, Wightman et al., 2024, JAMA.

The impact of introducing alcohol-free beer options in bars and public houses on alcohol sales and revenue: A randomised crossover field trial, De-Loyde et al., 2024, Addiction.

Opioid Coprescription Through Risk Mitigation Guidance and Opioid Agonist Treatment Receipt, Min et al., 2024, JAMA Network.

The association between alcohol consumption and all-cause mortality: An umbrella review of systematic reviews using lifetime abstainers or low-volume drinkers as a reference group, Sarich et al., 2024, Addiction.

Reasons for not entering opioid agonist treatment: A survey among high-risk opioid users in Finland, Prami et al., 2024, Nordic Studies on Alcohol and Drugs.

Modelling the amount of inputs needed for methamphetamine manufacture in Afghanistan, Pardo et al., 2024, Addiction.

Behavioural self-control training versus motivational enhancement therapy for individuals with alcohol use disorder with a goal of controlled drinking: A randomized controlled trial, Hammarberg et al., 2023, Addiction.

In the balance: No new diagnosis needed in addition to opioid use disorder to study harms associated with long-term opioid therapy, Drexler et al., 2023, Addiction.

Cannabis use disorder and adverse cardiovascular outcomes: A population-based retrospective cohort analysis of adults from Alberta, Canada, Bahji et al., 2023, Addiction.

Effects of the Connections program on return-to-custody, mortality and treatment uptake among people with a history of opioid use: Retrospective cohort study in an Australian prison system, Sullivan et al., 2023, Addiction.

Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder, Shulman et al., 2023, Addiction.

Rapid desorption and analysis for illicit drugs and chemical profiling of fingerprints by SICRIT ion source, Conway et al., 2023, Drug testing and analysis.

Benzodiazepine Discontinuation and Mortality Among Patients Receiving Long-Term Benzodiazepine Therapy, Maust et al., 2023, JAMA Networt.

Alcohol use in multiracial American youth compared with monoracial youth: A meta-analysis, Dobani et al., 2023, Addiction.

Trazodone for sleep disturbance in opioid dependent patients maintained on buprenorphine: A double blind, placebo-controlled trial, Goyal et al., 2023, Drug and Alcohol Dependence.

Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder, Foot et al., 2023, Addiction.

Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl, D’Onofrio et al., 2023, JAMA Network.

Weight change in a national cohort of U.S. Military Veterans engaged in medication treatment for opioid use disorder, Carr et al., 2023, Journal of Psychiatric Research.

The prevalence of constipation and its relation to sweet taste preference among patients receiving methadone maintenance treatment, Sason et al., 2023, Drug and Alcohol Dependence.

A conceptual framework for how structural changes in emerging acute substance use service models can reduce stigma of medications for opioid use disorder, Becker et al., 2023, Frontiers in Psychiatry.

„Get in and get out, get on with life“: Patient and provider perspectives on methadone van implementation for opioid use disorder treatment, Suen et al., 2023, International Journal of Drug Policy.

Methadone use for acute opioid withdrawal in Tshwane shelters during the COVID-19 lockdown, Siemens et al., 2023, South African Family Practice.

Can counter-advertising dilute marketing effects of alcohol sponsorship of elite sport: A field experiment, Dixon et al., 2023, Addiction.

Shifting drug markets in North America – a global crisis in the making? Meyer et al., 2023, International Journal of Mental Health Systems.

Labeled as “drug-seeking”: nurses use harm reduction philosophy to reflect on mending mutual distrust between healthcare workers and people who use drugs, Febres-Cordero et al., 2023, Frontiers in Public Health.

Combined use of cocaine and alcohol: A violent cocktail? A systematic review, van Amsterdam et al., 2023, Journal of Forensic and Legal Medicine.

Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials, Sharafi et al., 2023, Addiction.

Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children, Suarez et al., 2024, JAMA Network.

The effectiveness of workplace interventions for the prevention of alcohol use: A meta-analysis, Fellbaum et al., 2023, Addiction.

The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine-waivered providers in the United States, Stringfellow et al., 2023, Addiction.

Joint effects of substance use disorders and recent substance use on HIV viral non-suppression among people engaged in HIV care in an urban clinic, 2014–2019, Lesko et al., 2023, Addiction.

Healthcare costs and use before and after opioid overdose in Veterans Health Administration patients with opioid use disorder, Joyce et al., 2023, Addiction.

Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study, Miller et al., 2023, Implementation research and practice.

Understanding the use of telemedicine across different opioid use disorder treatment models: A scoping review, Teck et al., 2023, Journal of Telemedicine and Telecare.

Prevalence of cannabis use among young adults in Sweden comparing randomized response technique with a traditional survey, Andersson et al., 2023, Addiction.

Neonatal Outcomes after Medications for Opioid Use Disorder during Pregnancy in a State Women’s Prison Facility, 2016-2019, Knittel et al., 2023, Journal of addiction medicines.

Using a cascade of care framework to identify gaps in access to medications for alcohol use disorder in British Columbia, Canada, Socias et al., 2023, Addiction.

The implementation and public health impacts of cannabis legalization in Canada: a systematic review, Hall et al., 2023, Addiction.

Pregnancy and Postpartum Drug Overdose Deaths in the US Before and During the COVID-19 Pandemic, Han et al., 2023, JAMA Psychiatry.

Impulsivity in amphetamine use disorder: Examination of sex differences, Stewart et al., 2023, Addiction.

Leveraging existing provider networks in Europe to eliminate barriers to accessing opioid agonist maintenance therapies for Ukrainian refugees, Nikitin et al., 2023, Plos Global Public Health.

Methadone Maintenance and QT-Interval: Prevalence and Risk Factors—Is It Effective to Switch Therapy to Levomethadone?, Santin et al., 2023, biomedicines.

Efficacy and safety of combination behavioral activation for smoking cessation and varenicline for treating tobacco dependence among individuals with current or past major depressive disorder: A 2 × 2 factorial, randomized, placebo-controlled trial, Hitsman et al., 2023, Addiction.

Identifying and describing trajectories of alcohol use frequency and binge drinking frequency among those aged 15–30 years in a national cohort of US adolescents: A group-based trajectory modeling approach, Ranker et al., 2023, Addiction.

Alcohol’s harm to others in 2021: Who bears the burden?, Laslett et al., 2023, Addiction.

The Double-Edged Sword: Naloxone-Induced Noncardiogenic Pulmonary Edema, Marsalisi et al., 2023, Cureus.

Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis, Bharat et al., 2023, Addiction.

Psychedelics as Therapeutics—Potential and Challenges, Volkow et al., 2023, JAMA Psychiatry.

Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest, van Lemmen et al., 2023, Anesthesiology.

The Double-Edged Sword: Naloxone-Induced Noncardiogenic Pulmonary Edema, Marsalisi et al., 2023, Cureus.

Reduced anterior insular cortex volume in male heroin addicts: a postmortem study, Müller et al., 2023, European Archives of Psychiatry and Clinical Neuroscience.

Cardiac and mortality outcome differences between methadone, buprenorphine and naltrexone prescriptions in patients with an opioid use disorder, Wang et al., 2023, Clinical Psychology.

Impaired vision in children prenatally exposed to methadone: an observational cohort study, Hamilton et al., 2023, Nature.

Benzodiazepine use, quality of life and psychiatric symptom burden in oral and injectable opioid agonist treatment: a cross-sectional study, Meyer et al., 2023, Addiction Science & Clinical Practice.

Intravenous misuse of slow-release oral morphine capsules: how much morphine is injected? Bertin et al., 2023, Harm Reduction Journal.

‘I just thought that was the best thing for me to do at this point’: Exploring patient experiences with depot buprenorphine and their motivations to discontinue, Clay et al., 2023, International Journal of Drug Policy.

Understanding the differential effect of local socio-economic conditions on the relation between prescription opioid supply and drug overdose deaths in US counties, Fink et al., 2023, Addiction.

The relationship between problematic gambling severity and engagement with gambling products: Longitudinal analysis of the Emerging Adults Gambling Survey, Wardle et al., 2023, Addiction.

The predictive validity of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) for moderate- to high-risk cannabis, methamphetamine and opioid use after release from prison, Cumming et al., 2023, Addiction.

The impact of COVID-19 on trends in alcohol use disorder treatment in Veterans Health Administration, Perumalswami et al., 2023, Addiction.

Alcohol Cue Processing in Co-Occurring Bipolar Disorder and Alcohol Use Disorder, Mellick et al., JAMA Psychiatry, 2023.

Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders, Hatoum et al., 2023, Nature.

Zusammenhang zwischen Substanzkonsum und Zwangsmaßnahmen auf psychiatrischen Stationen, Betzler et al., 2022, Nervenarzt.

Public health concerns about Tuberculosis caused by Russia/Ukraine conflict, Paul et al., 2023, Health Science Reports.

HIV and HCV among drug users and people living in prisons in Germany 2022: WHO elimination targets as reflected in practice, Stöver et al., 2023, Harm Reduction Journal.

Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis, Bharat et al., 2023, Addiction.

Executive functioning, behavioural, emotional, and cognitive difficulties in school-aged children prenatally exposed to methadone, Spowart et al., 2023, Frotiers in Pediatrics.

Transitioning off methadone: A qualitative study exploring why patients discontinue methadone treatment for opioid use disorder, Thakrar et al., 2023, Journal of Substance Use and Addiction Treatment.

A retrospective study of pharmacological treatment in anorexia nervosa: 6-month and 12-month follow-up, Chiu et al., 2023, BMC Psychiatry.

The association between abused adults and substance abuse in Taiwan, 2000–2015, Chung et al., 2023, BMC Psychiatry.

The clustering of physical health conditions and associations with co-occurring mental health problems and problematic alcohol use: a cross-sectional study, Gomez et al., 2023, BMC Psychiatry.

Prevalence, severity, and associated factors of depression in newly diagnosed people living with HIV in Kilimanjaro, Tanzania: a cross-sectional study, Madundo et al., 2023, BMC Psychiatry.

Involvement and burden of informal caregivers of patients with mental illness: the mediating role of affiliated stigma, Kaggwa et al., 2023, BMC Psychiatry.

Trends in cocaine and crystal methamphetamine injection over time in a Canadian setting between 2008 and 2018, Bach et al., 2023, Journal of Substance Use Addiction Treatment.

Biomarkers of potential harm in people switching from smoking tobacco to exclusive e-cigarette use, dual use or abstinence: secondary analysis of Cochrane systematic review of trials of e-cigarettes for smoking cessation, Hartmann-Boyce et al., 2023, Addiction.

Returning home during the pandemic: a thematic analysis describing experiences of people with substance use disorders released early from New Jersey prisons during COVID-19, Bono et al., 2023, Health Justice.

Effect of Cognitive Behavioral Therapy for Insomnia on Alcohol Treatment Outcomes Among US Veterans, Miller et al., 2023, JAMA Psychiatry.

Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011–17, Lim et al., 2023, Addiction.

Cigarette pack size and consumption: a randomized cross-over trial, Lee et al., 2023, Addiction.

Classifying alcohol control policies enacted between 2000 and 2020 in Poland and the Baltic countries to model potential impact, Rehm et al., 2023, Addiction.

Diagnostic accuracy for self-reported methamphetamine use versus oral fluid test as the reference standard in a methamphetamine-dependent intervention trial population, Carter et al., 2023, Addiction

Drug use, drug use disorders, and treatment services in the Eastern Mediterranean region: a systematic review, Rostman-Abadi et al., 2023, Lancet Psychiatry.

Transformation of identity in substance use as a pathway to recovery and the potential of treatment for hepatitis C: a systematic review, Donaldson et al., 2023, Addiction.

‘Just snap out of it’ – the experience of loneliness in women with perinatal depression: a Meta-synthesis of qualitative studies, Adlington et al., 2023, BMC Psychiatry.

Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies, Degenhardt et al., 2023, Lancet Psychiatry.

Drug consumption in German cities and municipalities during the COVID-19 lockdown: a wastewater analysis, Oertel et al., 2023, Naunyn-Schmiedeberg’s Archives of Pharmacology.

A wastewater-based evaluation of the effectiveness of codeine control measures in Australia, Tscharke et al., 2023, Addiction.

Psychiatric presentations and admissions during the first wave of Covid-19 compared to 2019 in a psychiatric emergency department in Berlin, Germany: a retrospective chart review, Goldschmidt et al., 2023, BMC Psychiatry.

Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic, Hailu et al., 2023, JAMA Network Open.

Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review, Edinoff et al., 2023, Health Psychology Research.

Children born to women in opioid maintenance treatment: A longitudinal study of child behavioral problems and parenting stress, Sarfi et al., 2023, Frontiers in Pediatrics.

Specific polysubstance use patterns predict relapse among patients entering opioid use disorder treatment, Pan et al., 2022, Drug and Alcohol Dependence.

‘It’s not what you’d term normal smoking’: a qualitative exploration of language used to describe heated tobacco product use and associated user identity, East et al., 2023, Addiction.

Obdachlosigkeit und Drogen: gesundheitliche und soziale Maßnahmen, EMCDDA, 2022.

HANDLUNGSEMPFEHLUNGEN zum Umgang mit Crack-Konsum im Kontext der Drogen- und Suchthilfe, akzept e.V., 2022.

Reduced anterior insular cortex volume in male heroin addicts: a postmortem study, Müller et al., 2023, European Archives of Psychiatry and Clinical Neuroscience.

Patterns and Predictors of Heroin Use, Remission, and Psychiatric Health Among People with Heroin Dependence, Marel et al., 2023, International Journal of Mental Health and Addiction.

Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden, Grebely et al., 2023, International Journal of Drug Policy.

Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment, Haque et al., 2022, JAMA Network Open.

Medications for opioid use disorder during the war in Ukraine: a more comprehensive view on the government response, Ivanchuk, 2023, The Lancet Regional Health.

Responding to health policy recommendations on managing opioid use disorder during Russia’s invasion of Ukraine: Divergent responses from the frontline to the west, Ivasiy et al., 2023, Frontiers in Public Health.

Behavioral economics indices predict alcohol use and consequences in young men at 4-year follow-up, Gaume et al., 2022, Addiction.

Heroin Toxicity, Oelhaf et al., 2022, StatPearls.

Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data, Kranzler et al., 2022, Addiction.

Digital Addiction and Sleep, Dresp-Langley et al., 2022, International Journal of Environmental Research and Public Health.

Association of opioid use disorder with healthcare utilization and cost in a public health system, Miron et al., 2022, Addiction.

BDNF and its Role in the Alcohol Abuse Initiated During Early Adolescence: Evidence from Preclinical and Clinical Studies, Cutuli et al., 2022, Current neuropharmacology.

Does heroin-assisted treatment reduce crime? A review of randomized-controlled trials, Smart et al., 2022, Addiction.

Investigating the cost-effectiveness of three cessation interventions on a national scale using the Economics of Smoking in Pregnancy (ESIP) decision analytical model, Jones et al., 2022, Addiction.

Is Smartphone Addiction in the Younger Population a Public Health Problem? Loleska et al., 2021, Sciendo.

High rates of resumption of injecting drug use following release from prison among men who injected drugs before imprisonment, Curtis et al., 2022, Addiction.

Atypical opioid receptors: unconventional biology and therapeutic opportunities, Palmer et al., 2022, Pharmacology and Therapeutics.

E-cigarette use and conventional cigarette smoking among European students: findings from the 2019 ESPAD survey, Cerrai et al., 2022, Addiction.

Opioid Alternatives in Spine Surgery: A Narrative Review, Rajan et al., 2022, Journal of neurosurgical anesthesiology.

Definition matters: assessment of tolerance to the effects of alcohol in a prospective cohort study of emerging adults, O’Dean et al., 2022, Addiction.

Opioid-induced microglia reactivity modulates opioid reward, analgesia, and behavior, Green et al., 2022, Neuroscience and behavioral reviews.

Psychedelic Drug Legislative Reform and Legalization in the US, Siegel et al., 2022, JAMA Psychiatry.

Burden and treatment of chronic obstructive pulmonary disease among people using illicit opioids: matched cohort study in England, Lewer et al., 2022, BMJ Medicine.

Toward 90-90-90 Goals for Global Mental Health, Wagenaar et al., 2022, JAMA Psychiatry.

Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation, Randall et al., 2022, Journal of Addiction Medicine.

Predicting severe alcohol use disorders in primary care using number of heavy drinking days, Metz et al., 2022, Addiction.

Availability of opioid agonist treatment and critical incidents in Forensic Clinics for Dependency Diseases in Germany, Reiners et al., 2022, Frontiers in Psychiatry.

Validating transdermal alcohol biosensors: a meta-analysis of associations between blood/breath-based measures and transdermal alcohol sensor output, Yu et al., 2022, Addiction.

Medications for opioid use disorder during war in Ukraine: Innovations in public and private clinic cooperation, Bromberg et al., 2022, The Lancet Regional Health Europe.

Meta-analysis of associations between empathy and alcohol use and problems in clinical and non-clinical samples, Kumar et al., 2022, Addiction.

A Realist Review of How Community-Based Drug Checking Services Could Be Designed and Implemented to Promote Engagement of People Who Use Drugs, Masterton et al., 2022, International Journal of Environmental Research and Public Health.

Risk of non-fatal suicide attempt in individuals with substance use disorder: the roles of aggregate genetic liability and environmental exposures in a Swedish population-based cohort, Lannoy et al., 2022, Addiction.

Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis, Schoeler et al., 2022, Translational Psychiatry.

Does recreational cannabis legalization change cannabis use patterns? Evidence from secondary school students in Uruguay, Rivera-Aguirre et al., 2022, Addiction.

Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection, Beer et al., 2022, Journal of Viral Hepatitis.

Direct-acting antiviral treatment uptake and sustained virological response outcomes are not affected by alcohol use: A CANUHC analysis, Driedger et al., 2021, Canadian Liver Journal.

Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act, Craft et al., 2022, Addiction.

Does acute alcohol consumption increase risk-taking while gambling? A systematic review and meta-analysis, Horn et al., 2022, Addiction.

Association of Pharmacological Treatments and Hospitalization and Death in Individuals With Amphetamine Use Disorders in a Swedish Nationwide Cohort of 13 965 Patients, Heikkingen et al., 2022, JAMA Psychiatry.

Opioid use disorder during pregnancy: long-term developmental outcomes, Alinsky et al., 2021, Developmental medicine and child neurology.

Opioid use disorder: a neglected human immunodeficiency virus risk in American adolescents, Lloyd et al., 2021, AIDS.

Epigenetic Regulation of Circadian Clocks and Its Involvement in Drug Addiction, Saad et al., 2021, Genes.

MicroRNAs in drug addiction: Current status and future perspectives, Zhao et al., 2022, Pharmacology & Therapeutics.

Growing alcohol use preceding death by suicide among women compared with men: age-specific temporal trends, Lange et al., 2022, Addiction.

Insights from biosurveillance: non-fatal opioid overdoses in Rhode Island, King et al., 2022, Addiction.

The characteristics of people who inject drugs in the United Kingdom: changes in age, duration, and incidence of injecting, 1980–2019, using evidence from repeated cross-sectional surveys, Lewer et al., 2022, Addiction.

Age-based differences in quantity and frequency of consumption when screening for harmful alcohol use, Callinan et al., 2022, Addiction.

Brain lesions disrupting addiction map to a common human brain circuit, Joutsa et al., 2022, Nature Medicine.

Gabapentinoids: repeating mistakes of the past? Murnion et al., 2022, Addiction.

Novel Synthetic Opioids (NSO) Use in Opioid Dependents Entering Detoxification Treatment, Specka et al., 2022, frontiers in Psychiatry.

Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment, Meyer et al., 2022, Harm Reduction Journal.

Consensus recommendations for opioid agonist treatment following the introduction of emergency clinical guidelines in Ireland during the COVID-19 pandemic: a national Delphi study, Durand et al., 2022, International Journal of Drug Policy.

A transition of power in opioid substitution treatment: Clinic managers‘ views on the consequences of a patient choice reform, Andersson, 2022, Nordic Studies on Alcohol and Drugs.

Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada, Pilarinos et al., 2022, International Journal of Drug Policy.

Prävalenz von sexuell und durch Blut übertragenen Infektionen und Tuberkulose bei Menschen in Wohnungslosigkeit in Berlin – Erste Ergebnisse der Pilotstudie POINT.

Opioid Overdose, Schiller et al., 2022, StatPearls.

Effectiveness of a Stand-alone Telephone-Delivered Intervention for Reducing Problem Alcohol Use, Lubmann et al., 2022, JAMA Network.

How do people who use drugs receiving Opioid Medication Therapy perceive their treatment ? A multicentre study, Landreat et al., 2022, Harm Reduction Journal.

Association between GABA receptor delta subunit gene polymorphisms and heroin addiction, Xie et al., 2021, Neuroscience letters.

Microinduction of Buprenorphine/Naloxone: A Review of the Literature, Ahmed et al., 2021, The American Journal of addictions.

From drug prohibition to regulation: a public health imperative, Malinowska-Sempruch et al., 2022, The Lancet.

Arrhythmogenesis and Prolonged Repolarization From Synthetic Opioids: Finally Sorted? Eckhardt, 2022, Journal of the American Heart Association.

Association of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use Disorders, Raji et al., 2022, The American Journal of Medicine.

Changes in the development of opioid tolerance on re-exposure among people who use heroin: A qualitative study, Kesten et al., 2022, PLoS One.

Association Between Brain Structure and Alcohol Use Behaviors in Adults, Mavromatis et al., 2022, JAMA Network.

What lessons from Europe’s experience could be applied in the United States in response to the opioid addiction and overdose crisis?, van den Brink et al., 2022, Addiction.

Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder, Ellis et al., 2022, Drug and alcohol Dependence.

The Role of Gabapentinoids in the Substance Use Pattern of Adult Germans Seeking Inpatient Detoxification Treatment – A Pilot Study, Bonnet et al., 2022, Journal of psychoactive drugs.

Cocaethylene: When Cocaine and Alcohol Are Taken Together, Muacevic et al., 2022, Cureus.

Extending a lifeline to people with HIV and opioid use disorder during the war in Ukraine, Altice et al., 2022, The Lancet.

Characteristics of White Matter Integrity During Different Phases of Abstinence in Heroin Use Disorders, Zhu et al., 2022, Addiction Medicine.

Frontal Lobe Functions, Demoralization, Depression and Craving as Prognostic Factors and Positive Outcomes of Patients with Heroin Use Disorder Receiving 6 Months of Methadone Maintenance Treatment, Chang et al., 2022, International Journal of Environmental Research and Public Health.

Exploring why patients in heroin-assisted treatment are getting incarcerated—a qualitative study, Meyer et al., 2022, BMC Psychiatry.

Neuropsychoimaging Measures as Alternatives to Drug Use Outcomes in Clinical Trials for Addiction, Goldstein, 2022, Jama Psychiatry.

Heroin-Induced Acute Pancreatitis, Ciobanu et al., 2021, Cureus.

Crystal methamphetamine use subgroups and associated addiction care access and overdose risk in a Canadian urban setting, Brooks et al., 2022, Drug and alcohol dependence.

The Opioid Crisis: Prevalence and Markets of Opioids, Gardner et al., 2022, Forensic science review.

Opioid use disorder and the brain: a clinical perspective, Herlinger et al., 2022, Addiction.

Can NSAIDs and Acetaminophen Effectively Replace Opioid Treatment Options for Acute Pain? Pergolizzi et al., 2021, Expert opinion on pharmacotherapy.

Vulnerability to addiction, Maldonado et al., 2021, Neuropharmacology.

The effects of cannabis and alcohol on driving performance and driver behaviour: a systematic review and meta-analysis, Simmons et al., 2022, Addiction.

Protracted abstinence in males with an opioid use disorder: partial recovery of nucleus accumbens function, Tolomeo et al., 2022, Translation Psychiatry.

Multicenter Observational/Exploratory Study Addressed to the Evaluation of the Effectiveness and Safety of Pharmacological Therapy in Opioid-Dependent Patients in Maintenance Therapy in Southern Italy, Maqoud et al., 2022, Pharmaceutics.

Stigma and ART initiation among people with HIV and a lifetime history of illicit drug use in Saint-Petersburg, Russia–A prospective cohort analysis, Vetrova et al., 2022, International Journal of Drug Policy.

The Impact of Expanding Opioid Agonist Therapies on HIV epidemic and mortality in Ukraine: a Modeling study, Tan et al., 2020, Lancet HIV.

Opioid Use Disorder Increases Readmissions After Cardiac Surgery: A Call to Action, Dewan et al., 2022, The Annals of thoracic surgery.

Relationship between psychological factors and perceived stigma of addiction among women with substance use disorders, Thailand, Yangyuen et al., 2022, Journal of Education and Health Promotion.

ADVANCE integrated group intervention to address both substance use and intimate partner abuse perpetration by men in substance use treatment: a feasibility randomised controlled trial, Gilchrist et al., 2021, BMC Public Health.

Suicide Attempt and Risk of Substance Use Disorders Among Female Youths, Auger et al., 2022, JAMA Network.

Characterising the use of varenicline: an analysis of the Australian dispensing claims data, Gobarani et al., 2022, Addiction.

Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia, Chaillon et al., 2021, Addiction.

Similar COVID-19 incidence to the general population in people with opioid use disorder receiving integrated outpatient clinical care, Vallecillo et al., 2022, Drug and Alcohol Dependence Reports.

Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients’ and prescribers’ experiences with changes in unsupervised dosing, Corace et al., 2022, International Journal of Drug Policy.

Prevalence of Respiratory Disorders during Sleep among Subjects of Methadone Maintenance Therapy Program, Talaei et al., 2021, Addiction & Health.

Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial, Skulberg et al., 2022, Addiction.

Golden opportunity for intervention? Identifying vitamin D deficiency in patients with substance use disorders in hospital, Smith et al., 2022, BMJ Open Quality.

Meeting people where they are: implementing hospital-based substance use harm reduction, Perera et al., 2022, Harm Reduction Journal.

Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse, Tay et al., 2022, Substance Abuse and Rehabilitation.

Inhalative Suchtmittel – eine Herausforderung für die Lunge, Kemény et al., 2022, Pneumologe.

Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine TrialsA Systematic Review and Meta-analysis, Haas et al., 2022, JAMA Network.

No party, no drugs? Use of stimulants, dissociative drugs, and GHB/GBL during the early COVID-19 pandemic, Bendau et al., 2022, International Journal of Drug Policy.

Global, regional, and national consumption of controlled opioids: a cross-sectional study of 214 countries and non-metropolitan territories, Richards et al., 2022, British Journal of Pain.

Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials, Thomas et al., 2021, Addiction.

Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model, Alexander et al., 2021, Addiction.

The Association between Chronic Heroin Smoking and Chronic Obstructive Pulmonary Disease, Bitar et al., 2021, Journal of Pharmay and Bioallied Sciences.

A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder, Chawar et al., 2021, Addiction Science and Clinical Practice.

Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada, Kurz et al., 2021, Journal of Substance Abuse Treatment.

Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence, Farrell et al., 2022, International Journal of Drug Policy.

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report, Menard et al., 2021, The Mental Health Clinician.

Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives, Aronowitz et al., 2021, Harm Reduction Journal.

Opioid free anesthesia: evidence for short and long-term outcome, Bugada et al., 2021, Minerva Anestiologica.

Optimizing Treatment for Opioid Use Disorder, Brady, 2021, The American Journal of Psychiatry.

The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy, Cheetham et al., 2021, Dovepress.

Does heroin-assisted treatment reduce crime? A review of randomized-controlled trials, Smart et al., 2021, Addiction.

Addiction as a brain disease revised: why it still matters, and the need for consilience, Heilig et al., 2021, Neurophsychopharmacology.

Substance use disorder and the baby boom generation: Does Berlin outpatient addiction care face a sustained change? Specht et al., 2021, Drug and Alcohol.

Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study, Koeck et al., 2021, Frontiers in Psychiatry.

Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey, Evens et al., 2021, Frontiers in Psychiatry.

Mitochondrial Genotoxicity of Hepatitis C Treatment among People Who Inject Drugs, Durand et al., 2021, Journal of Clinical Medicine.

Estimating the number of children in households with substance use disorders in Germany, Kraus et al., 2021, Child and Adolescent Psychiatry and Mental Health.

Different drugs come with different motives: Examining motives for substance use among people who engage in polysubstance use undergoing methadone maintenance therapy (MMT), Mahu et al., 2021, Drug and Alcohol Dependence.

Motives for opioid use explain the relation between borderline personality disorder pathology and opioid use problems, Scamaldo et al., 2021, Psychiatry Research.

Loneliness, Mental Health, and Substance Use among US Young Adults during COVID-19, Horigian et al., 2021, Journal of Psychoactive Drugs.

Investigating Mental Health Implications for Drug Court Participants, Humenik et al., 2020, International Journal of Offender Therapy and Comparative Criminology.

Mental health and substance use affect perioperative opioid demand in upper extremity trauma surgery, Cunningham et al., 2021, Journal of Shoulder and Elbow Surgery.

Did drug use increase following COVID-19 relaxation of methadone take-out regulations? 2020 was a complicated year, Bart et al., 2021, Journal of Substance Abuse Treatment.

Use of Medication-Assisted Treatment in Emergency Departments, Substance Abuse and Mental Health Services Administration (SAMHSA).

Substance abuse and cancer, Moussas et al., 2017, Psychiatriki.

Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19, Brothers et al., 2021, Journal of Substance Abuse Treatment.

Closing the brain–heart loop: Towards more holistic models of addiction and addiction recovery, Eddie et al., 2020, Addiction Biology.

Factors associated with testing for HIV and hepatitis C among behaviorally vulnerable men in Germany: a cross-sectional analysis upon enrollment into an observational cohort, Crowell et al., 2021, AIDS Research and Therapy.

Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment, Huang et al., 2021, Frontiers in Endocrinology.

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting – a case series, Soyka et al., 2021, The American Journal of Drug and Alcohol Abuse.

Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience, Sandmann et al., 2021, Open Forum Infection Diseases.

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis, Santro et al., 2021, JAMA Psychiatry.

Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department, Hawk et al., 2021, Annals of Emergency Medicine.

Transition From Full Mu Opioid Agonists to Buprenorphine in Opioid Dependent Patients—A Critical Review, Soyka, 2021, Frontiers in Pharmacology.

Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review, Sarris et al., 2020, BMC Psychiatry.

Risk Factors for Opioid-Use Disorder and Overdose, Webster, 2017, Anesthesia & Analgesia.

Management and monitoring of opioid use in pregnancy, 2020, Rausgaard et al., Acta Obstetricia et Gynecologica Scandinavica.

Detachment, peer pressure, and age of first substance use as gateways to later substance use, Gallegos et al., 2021, Drug and Alcohol Dependence.

Rohypnol-induced sexual dysfunction is via suppression of hypothalamic-pituitary-testicular axis: An experimental study in rats, Oluwole et al., 2021, Andrologia.

Advances in the science and treatment of alcohol use disorder, Witkiewitz et al., 2019, Science Advances.

The Psychonauts’ Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity, Catalani et al., 2021, Pharmaceuticals.

Case Report: CBD Cigarettes for Harm Reduction and Adjunctive Therapy in a Patient With Schizophrenia and Substance Use Disorder, Meyer et al., 2021, Frontiers in Psychiatry.

Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial, Ray et al., 2021, The American Journal of Psychiatry.

The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here? Tracy et al., 2021, Journal of Substance Abuse Treatment.

Initiating buprenorphine to treat opioid use disorder without prerequisite withdrawal: a systematic review, Adams et al., 2021, Addiction Science & Clinical Practice.

Opioid Toxidrome Following Grapefruit Juice Consumption in the Setting of Methadone Maintenance, Ershad et al., 2020, Journal of Addiction Medicine.

Factors associated with opioid overdose during medication-assisted treatment: How can we identify individuals at risk? Au et al., 2021, Harm Reduction Journal.

Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department, Hawk et al., 2021, Annals of Emergency Medicine.

Mobile methadone dispensing in Delhi, India: implementation research, Rao et al., 2021, Bulletin of the World Health Organization.

The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases, Stöver et al., 2021, Harm Reduction Journal.

Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy, Schmidbauer et al., 2021, PLOS One.

The epidemic of fentanyl misuse and overdoses: challenges and strategies, Volkow, 2021, World Psychiatry.

Opioid-Induced Tolerance and Hyperalgesia, Mercadante et al., 2019, CNS Drugs.

Opioid utility function: methods and implications, Jan van Dam et al., 2020, Annals of Palliative Medicine.

Opioid Therapy in Acute and Chronic Pain, Nafziger et al., 2018, The Journal of Clinical Pharmacology.

When less is more: Opioid use in the emergency department, Patanwala, 2019, American Journal of Health-System Pharmacy.

Buprenorphine Treatment for Opioid Use Disorder: An Overview, Shulman et al., 2019, CNS Drugs.

Use of cognitive enhancers: methylphenidate and analogs, Carlier et al., 2019, European Review for Medical and Pharmaceutical Sciences.

Reprint of: Biotechnologies and the future of opioid addiction treatments, Wolfe et al., 2021, International Journal of Drug Policy.

Quality of Life in Opioid Replacement Therapy: A Naturalistic Cross-Sectional Comparison of Methadone/Levomethadone, Buprenorphine, and Diamorphine Patients, Guillery et al., 2021, European Addiction Research.

Injecting drug use, the skin and vasculature, Robertson et al., 2020, Addiction.

Reorganization of Substance Use Treatment and Harm Reduction Services During the COVID-19 Pandemic: A Global Survey, Radfar et al., 2021, Frontiers in Psychiatry.

Methadone overdose in patients following methadone mainte-nance treatment:A three years overview in the district of Bari (South-Italy), Favia et al., 2021, Clinica Terapeutica.

Use of sustained release dextroamphetamine for the treatment of stimulant use disorder in the setting of injectable opioid agonist treatment in Canada: a case report, Palis et al., 2021, Harm Reducation Journal.

Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries, Fonseca et al., 2021, Frontiers in Psychiatry.

Do gabapentin or pregabalin directly modulate the µ receptor?, Manandhar et al., 2021, Peer J.

International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder, Özgen et al., 2020, European Addiction Research.

Availability of Illegal Drugs During the COVID-19 Pandemic in Western Germany, Scherbaum et al., 2021, Frontiers in Psychiatry.

Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway, Chalabianloo et al., 2021, Substance Abuse Treatment, Prevention, and Policy.

Gender Differences on Methadone Maintenance Treatment Outcome among Patients with Opioid use Disorder: A Systematic Review, Rizal et al., 2020, Journal of Pharmacy & BioAllied Sciences.

New Approaches in Drug Dependence: Opioids, Mielau et al., 2021, Current Addiction Reports.

Prevalence and Characteristics of Chronic Pain in Buprenorphine and Methadone-Maintained Patients, Delorme et al., 2021, Frontiers in Psychiatry.

Benzodiazepine Use in Opioid Maintenance Treatment Programme: Risks and Clinical Outcomes, Oliveira et al., 2021, Acta médica portuguesa.

Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis, Santo et al., 2021, JAMA Psychiatry.

Considering the harms of our habits: The reflexive urine drug screen in opioid use disorder treatment, Khatri et al., 2020, Journal of Substance Abuse Treatment.

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies, Fava et al., 2020, Molecular Psychiatry.

Substitution treatment for opioid dependence with slow-release oral morphine: Retention rate, health status, and substance use after switching to morphine, Lehmann el al., 2021, Journal of Substance Abuse Treatment.

Methadone, Metoclopramide and Metronidazole Interaction Causing Torsades de Pointes, Gnanapandithan el al., 2021, Clinics and Practice.

Behandlung opioidabhängiger Inhaftierter – Einstellungen und Behandlungspraxis des medizinischen Personals in bayerischen Justizvollzugsanstalten, Weiss et al., 2021, Gesundheitswesen.

Empfehlungen zur substitutionsgestützten Behandlung bei Minderjährigen, Erbas et al., 2021, Bayerische Akademie für Sucht- und Gesundheitsfragen.

Factors Associated with Low Bone Density in Opioid Substitution Therapy Patients: A Systematic Review, Ramli et al., 2021, International Journal of Medical Sciences.

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine, Lintzeris et al., 2021, JAMA Network Open.

Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors, Beard et al., 2021, Addiction.

Folgen der COVID-19-Pandemie für Menschen mit Schizophrenie, Demenz und Abhängigkeitserkrankungen, Adorjan et al., 2021, Nervenarzt.

COVID‐19 Vaccination among socially vulnerable people who use drugs, Arcadepani et al., 2021, Addiction.

Addiction as a brain disease revised: why it still matters, and the need for consilience, Heilig et al., 2021, Neuropsychopharmacology.

Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis, Stone et al., 2021, Lancet Psychiatry.

Prolonged-release buprenorphine formulations: Perspectives for clinical practice, Chappuy et al., 2020, Therapie.

Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis, Link et al., 2020, American Journal of Obstetrics & Gynecology.

The dopamine theory of addiction: 40 years of highs and lows, Nutt et al., 2015, Nature Reviews Neuroscience.

Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone, Rolland et al., 2021, Drug and Alcohol Dependence.

Tapentadol:An Opioid of Abuse Acquired Online, Ansley et al., 2020, The Primary Care Companion for CNS Disorders

Mindfulness meditation improves emotion regulation and reduces drug abuse, Tang et al., 2016, Drug and Alcohol Dependence.

Ibogaine and addiction in the animal model, a systematic review and meta-analysis, Belgers et al., 2016, Translational Psychiatry.

Historical Review: Opiate Addiction and Opioid Receptors, Wang, 2018, Cell Transplantation.

Dopaminylation of histone H3 in ventral tegmental area regulates cocaine seeking, Lepack et al., 2020, Science.

Impact of Continuing Care on Recovery From Substance Use Disorder, McKay, 2021, Alcohol research.

Mobile van delivery of extended-release buprenorphine and extended-release naltrexone for youth with OUD: An adaptation to the COVID-19 emergency, Wenzel et al., 2021, Journal of Substance Abuse Treatment.

Filling the Gaps: Planning for the Disaster Health Needs of Patients Taking Opioids and People Using Illicit Drugs

Estimated televised alcohol advertising exposure in the past year and associations with past 30-day drinking behavior among American adults: results from a secondary analysis of large-scale advertising and survey data, Niederdeppe et al., 2021, Addiction.

Peer recovery coaches in general medical settings: Changes in utilization, treatment engagement, and opioid use, Magidson et al., 2021, Journal of Substance Abuse Treatment.

Evidence of increased Fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario, Canada, Morin et al., 2020, The International Journal on Drug Policy.

Creating an ethical culture to support recovery from substance use disorders, Williamson, 2020, Journal of Medical Ethics.

Is substance use changing because of the COVID‐19 pandemic? Conceptual and methodological considerations to delineating the impact of the Covid‐19 pandemic on substance use and abuse

Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE), Schulte et al., 2020, Frontiers in Psychiatry.

Forty-eight years of research on psychosocial interventions in the treatment of opioid use disorder: A scoping review, Wild et al., 2021, Drug and Alcohol Dependence.

Archive: Publikation

April 2025

März 2025

Februar 2025

Januar 2025

Dezember 2024

November 2024

Oktober 2024

September 2024

August 2024

Juli 2024

Juni 2024

Mai 2024

April 2024

März 2024

Februar 2024

Januar 2024

Dezember 2023

November 2023

Oktober 2023

September 2023

August 2023

Juli 2023

Juni 2023

Mai 2023

April 2023

März 2023

Februar 2023

Januar 2023

Dezember 2022

November 2022

Oktober 2022

September 2022

August 2022

Juli 2022

Juni 2022

Mai 2022

April 2022

März 2022

Februar 2022

Januar 2022

Dezember 2021

November 2021

Oktober 2021

September 2021

August 2021

Juli 2021

Juni 2021

Mai 2021

April 2021

März 2021

Februar 2021

Melden Sie sich jetzt für unseren Newsletter an